Anemia is a common condition in patients with cancer, and its correction through either transfusion with packed red blood cells or the administration of erythropoiesis-stimulating agents (ESAs) is a supportive care measure. The purpose of the guidelines is to operationalize the evaluation and treatment of anemia in cancer patients and to enable patients and clinicians to evaluate treatment options in the context of risks and benefits. The updated guidelines include a number of important changes that respond to new FDA recommendations limiting the use of ESAs in cancer patients. Updates also include new tables on the risks and benefits of ESAs versus red blood cell transfusion and recommendations for administering parenteral iron products.
For the most recent version of the guidelines, please visit NCCN.org
If the inline PDF is not rendering correctly, you can download the PDF file here.
The University of Alabama at Birmingham (UAB) Comprehensive Cancer Center was designated one of the first 11 “comprehensive” cancer centers in 1972. Since then, the Center has become a national leader in research, treatment, and education.
Today, the UAB Comprehensive Cancer Center is the only National Cancer Institute (NCI)-designated cancer center in a 5-state region: Alabama, Arkansas, Georgia, Louisiana, and Mississippi.
The Center, which emphasizes multidisciplinary research and patient care, has grown to more than 300 faculty members (including basic and clinical scientists and physicians). It encompasses more than 150,000 square feet of research space and has more than $100 million in annual research funding. Faculty expertise includes tumor biology, virology/gene therapy, immunobiology, targeted immunotherapy, drug discovery and experimental therapeutics. Cancer Center Director Edward Partridge, MD (second photo on cover), is a nationally recognized expert in the fields of women's cancers and outreach among minorities and underserved populations.
UAB is the recipient of 3 NCI SPORE (Specialized Program of Research Excellence) grants: breast, brain tumor, and pancreatic cancer (P20).